Significance of the Sentinel Lymph Node Biopsy in Early Breast Carcinomas

Česká verzia

Authors: P. Chválny; V. Straka ¹; R. Donát ¹; J. Malina ¹; D. Dyttert ¹; M. Sabol ¹; B. Duchaj ²; J. Veselý ²; V. Lehotská ³; K. Rauová ³; Š. Galbavý ⁴; D. Macák ⁴; V. Ďurčány ⁴; C. Bíró ⁴
Authors place of work: Klinika onkologickej chirurgie LF UKo a OÚSA, Bratislava, Slovenská republika prednosta: doc. MUDr. Štefan Durdík, Ph. D. ; Klinika onkologickej chirurgie LF UKo a OÚSA, Bratislava, Slovenská republika primár: doc. MUDr. Vladimír Straka, CSc. ¹; Klinika nukleárnej medicíny LF UKo a OÚSA, Bratislava, Slovenská republika prednostka: doc. MUDr. Izabela Makaiová, CSc. ²; II. rádiologická klinika LF UKo a OÚSA, Bratislava, Slovenská republika prednosta: doc. MUDr. Viera Lehotská, Ph. D. ³; Ústav laboratórnych a vyšetrovacích metód LF UKo a OÚSA, Bratislava, Slovenská republika prednosta: prof. MUDr. Štefan Galbavý, CSc. ⁴
Published in the journal: Rozhl. Chir., 2010, roč. 89, č. 7, s. 395-401.
Category: Monothematic special - Original

Summary

We present our experience regarding sentinel lymph node biopsy (SLNB) at St. Elizabeth Institute of Oncology during 48 months. From January 1st, 2006 until December 31st, 2009, we had performed SLNB in 269 patients. Primary tumour size was 0.3–3.5cm including non-invasive breast carcinoma (i.e. TIS, T1 and T2 of TNM classification). Invasive carcinoma accounted for 255 (94.8%) cases, while non-invasive carcinoma for 14 (5.2%) cases. From total of 269 patients with invasive carcinoma, we used validation method in 157 (72.7%). In 255 patients with invasive carcinoma, sentinel node was not identified in 4 (1.6%) cases – in 1 patient with T1 invasive carcinoma and in 3 patients with T2 tumours. False negativity of sentinel node in T1 tumours was 4.3%. The incidence of macrometastases in sentinel nodes was confirmed using standard histopathologic examination with hematoxylin-eosin stain. In negative instances, the examination was then completed with serial sections and immunohistochemistry using cytoskeletal antibodies for confirmation of presence of micrometastases. In 6 (2.4%) cases, we found micrometastase in originally negative sentinel lymph node. Subsequent axillary dissection has not confirmed non-sentinel nodes involvement.

Key words:
sentinel lymph node biopsy – breast carcinoma – validation method – micrometastases

Zdroje

1. American Joint Committee for Cancer Staging and End Results, Clinical Highlights from the National Cancer Data Base. CA Cancer J. Clin., 49, 1999, s. 145–158.

2. ASCO 2009: Sentinel Node Micrometastases Need Additional Treatment in Breast Cancer American Society of Clinical Oncology, June 4, 2009 (Orlando, Florida) http://www.medscape.com/viewarticle/703954

3. Ansari, B., Ogston, S. A., Purdie, C. A., Adamson, D. J., Brown, D. C., Thompson, A. M. Meta-analysis of sentinel node biopsy in ductal carcinoma in situ of the breast. British Journal of Surgery, 2008, 95, 547–554.

4. Barclay, L., Vega, Ch. Lymphatic Mapping, Sentinel Lymphadenectomy Before Neoadjuvant Chemotherapy May Be Accurate in Large Breast Cancers. Am. J. Surg., 2005; 190: 371–375.

5. Bauer, T. W., Spitz, F. R., Callans, L. S., et al. Subareolar and peritumoral injection identify similar sentinel nodes for breast cancer. Ann. Surg. Oncol., 2002, 9: 169–176.

6. Bland, K., Copeland, E. The Breast. London, Saunders 3rd edition. 2003, 1049 pp.

7. Cipolla, C., Vieni, S., Fricano, S., Cabibi, D., Graceffa, G., Costa, R., Latteri, S. The accuracy of sentinel lymph node biopsy in the treatment of multicentric invasive breast cancer using a subareolar injection of tracer. World J. Surg., 2008, Nov; 32(11): 2483–2487.

8. Colleoni, M., Rotmensz, N., Peruzzotti, G., et al. Size of breast cancer metastases in axillary lymph nodes: Clinical relevance of minimal lymph node involvement. J. Clin. Oncol., 2005, 23: 1379–1389.

9. Cote, R. J., Peterson, H. F., Chaiwun, B., et al. Role of immunohistochemical detection of lymph-node metastases in management of breast cancer: International Breast Cancer Study Group. Lancet, 1999, 354: 896–900.

10. Cox, C. E., Kiluk, J. V., Riker, A. I., et al. Significance of sentinel node micrometastases in human breast cancer. J. Am. Coll. Surg., 2008, 206: 261–268.

11. Cserni, G., Gregori, D., Merletii, F., et al. Meta-analysis of non-sentinel node metastases associated with micrometastastis sentinel node in breast cancer. Br. J. Surg. 2004; 91.

12. Červinka, V., Šťastný, K., Šiller, J., a kol. Sentinelová uzlina v praxi. Onkológia (Bratisl.), 2006, roč. 1 (4): 259–261.

13. Červinka, V., Šťastný, K., Nechvátal, L., Pellant, A., Ryška, A. Význam imunohistochemického vyšetření při detekci metastáz v sentinelových uzlinách karcinomu prsu. Onkologia (Bratisl.), 2008, roč. 3 (4): 268–269.

14. de Boer, M., et al. Micrometastases and isolated tumor cells: relevant and robust or rubbish? (MIRROR) Preliminary results of the MIRROR study from the Dutch breast cancer trialists group. SABCS 2008 Abstracts. 70 s. Abstract 23.

15. Fait, V., Chrenko, V., Gaťek, J. Sentinelová biopsie u karcinomu prsu a neoadjuvantní chemoterapie. Klinická onkologie, 2005, č. 3, 77–79.

16. Ferrari, A., Dionigi, P., Rovera, F. Multifocality and multicentricity are not contraindications for sentinel lymph node biopsy in breast cancer surgery. World Journal of Surgical Oncology, 2006, 4: 79.

17. Gipponi, M., Canavese, G., Lionetto, R. The role of axillary lymph node dissection in breast cancer patients wit sentinel lymph node micrometastases. Eur. J. Surg. Oncol., 2006; 32: 143–147.

18. Gobardhan, P. D., Elias, S. G., Madsen, E. V. E., et al. Prognostic value of micrometastases in sentinel lymph nodes of patients with breast carcinoma: A cohort study. Ann. Oncol., 2009, 20: 41–48.

19. Hohenberger, P., Reuhl, Th., Markwardt, P. et al. Sentinel node detection beim Mammacarcinom, Chirurg, 1998, 69: 708–716.

20. Holwitt, D. M., Gillanders, W. E., Aft, R. L., Eberlein, T. J., Margenthaler, J. A. Sentinel lymph node biopsy in patients with multicentric/multifocal breast cancer: low false-negative rate and lack of axillary recurrence. Am. J. Surg., 2008, Oct; 196(4): 562–565.

21. Chen, S. L., Hoehne, F. M., Giuliano, A. E. The prognostic signficiance of micrometastases in breast cancer: A SEER population-based analysis. Ann. Surg. Oncol., 2007, 14, 3378–3384.

22. Julínek, S. Mikrometastázy karcinomu prsu v sentinelové uzlině: současné kontroverze. Prakt. Gyn. 2006; 10(1).

23. Meijnen, P., Rutgers, E. J. Meta-analysis of sentinel node biopsy in ductal carcinoma in situ of the breast. Br. J. Surg., 2008; 95: 547–554.

24. Menard, J. P., Extra, J. M., Jacquemier, J., Buttarelli, M., Lambaudie, E., Bannier, M., Brenot Rossi, I., Houvenaeghel, G. Sentinel lymphadenectomy for the staging of clinical axillary node-negative breast cancer before neoadjuvant chemotherapy. Eur. J. Surg. Oncol., 2009, Jan 19.

25. Nasser, I. A., Lee, A. K., Bosari, S., et al. Occult axillary lymph node metastases in „node-negative” breast carcinoma. Hum. Pathol., 1993, 24: 950–957.

26. National Cancer Date Base 2009, http://www.facs.org/cancer/

27. Rimarčík, M. Štatistika pre prax. Enigma, 2007, 81–82, kapitola 3. 2. 10.

28. San Antonio Breast Cancer Symposium (SABCS) 32nd Annual meeting, December 9 - 13, 2009; San Antonio, Texas, Nodal Micrometastases Raise Breast Cancer Recurrence Risk,

http://www.medpagetoday.com/MeetingCoverage/SABCS/12195

29. Schauer, A. J., Becker, W., Reiser, M., Possinger, K. The Sentinel Lymph Node Concept, Springer-Verlag Berlin Heidelberg 2005, ISBN 3-540-41041-4.

30. Thoma, B. J. If Sentinel Node Micrometastases Are the Question, Are Clinical Trials the Answer? Allegheny General Hospital, Pittsburg, PA. Journal Of Clinical Oncology, Vol. 27, 2009.

31. Tjan-Heijnen, V. C., Pepels, M. J., de Boer, M., et al. Impact of omission of completion axillary lymph node dissection (cALND) or axillary radiotherapy (axRT) in breast cancer patients with micrometastases (pN1mi) or isolated tumor cells (pN0(i+) in the sentinel lymph node (SN): Results from the MIRROR study. Presented at the 2009 annual meeting of the American Society of Clinical Oncology, May 29–June 2, 2009.